

## PRESS RELEASE

# FB Health rebrands to Neuraxpharm Italy

# Neuraxpharm Group makes a step forward by rebranding its subsidiary also in Italy

**October 23, 2018.** FB-Health, an Italian-based specialty pharmaceutical company focused on the prevention and treatment of diseases in the fields of neurology, geriatrics, psychiatry and child neuropsychiatry, has just rebranded to Neuraxpharm Italy.

Neuraxpharm Italy, located in Ascoli Piceno, has a 100% CNS-oriented portfolio of nutraceuticals and branded generics. With the rebranding in Italy, the company demonstrates its commitment to the CNS area through its new name.

The whole Group has recently rebranded to Neuraxpharm. Neuraxpharm is a leading CNS group with more than 30 years of experience and with a strong presence in the main European markets. Neuraxpharm will position itself as the specialist partner of choice in CNS with more than 100 CNS molecules offered in the European market.

Marco Marchetti, Managing Director of Neuraxpharm Italy, remarked that "we are convinced that the rebranding of our company further reinforces our leading CNS position in Italy. Our mission is to improve the quality of life for patients suffering from CNS disorders through our nutraceuticals, like *Vivimind®* and *Seripnol®*, and pharmaceutical products. The key opinion leaders in the fields of neurology, geriatrics, psychiatry and child neuropsychiatry, with whom Neuraxpharm Italy has a solid relationship, fully support the rebranding".

In this regard, Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, commented that "this rebranding in Italy is of strategic importance for the whole Group, as the Italian is among the top 5 CNS markets in Europe and helps us to position ourselves as a dominant player in the CNS area as well as to be more easily identified".

Being part of a large Group, Neuraxpharm Italy is already benefiting from a wide portfolio by adding more CNS products to the existing business in Italy and will also launch several new products in the coming years.

#### **About Neuraxpharm Italy**

Neuraxpharm Italy is an Italian-based specialty pharmaceutical company founded in 2010 focused on the research, development and commercialization of innovative nutraceuticals and pharmaceuticals in Italy for the prevention and treatment of pathologies with particular attention to neurological, geriatric and psychiatric and child neuropsychiatric targets.

### (www.neuraxpharm.it)

#### **About Neuraxpharm**

Neuraxpharm is a leading European specialty pharmaceutical company in the treatment of central nervous system disorders (CNS) with a direct presence in Germany, Spain, Italy, France and Poland. Consolidated as a group in 2016 and backed by funds advised by Apax Partners, Neuraxpharm has a unique understanding of the CNS market of over 30 years.



Neuraxpharm develops and commercializes in Europe branded and generic CNS pharmaceuticals and nutraceuticals, offering a wide range of effective, differentiated and affordable CNS treatments, aimed at patients as well as health professionals and industry partners.

Present in more than 50 countries, Neuraxpharm also manufactures pharmaceutical forms and active pharmaceutical ingredients indicated for the CNS and respiratory areas.

www.neuraxpharm.com